120 related articles for article (PubMed ID: 37279701)
21. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
Matsumoto J; Iwata N; Watari S; Ushio S; Shiromizu S; Takeda T; Hamano H; Kajizono M; Araki M; Nasu Y; Ariyoshi N; Zamami Y
Eur Urol Focus; 2023 Jan; 9(1):141-144. PubMed ID: 35915038
[TBL] [Abstract][Full Text] [Related]
22. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
23. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
24. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors and Hypothyroidism: An Analysis of the Japanese Pharmacovigilance Database.
Tanaka H; Tani A; Onoda T; Ishii T
In Vivo; 2024; 38(2):917-922. PubMed ID: 38418113
[TBL] [Abstract][Full Text] [Related]
26. Current status of adverse event profile of tacrolimus in patients with solid organ transplantation from a pharmacovigilance study.
Kambara H; Oyama S; Inada A; Niinomi I; Wakabayashi T; Hosohata K
Int J Clin Pharmacol Ther; 2021 Dec; 59(12):753-759. PubMed ID: 34402788
[TBL] [Abstract][Full Text] [Related]
27. Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database.
Sato K; Mano T; Iwata A; Toda T
J Alzheimers Dis; 2021; 82(3):1333-1344. PubMed ID: 34151816
[TBL] [Abstract][Full Text] [Related]
28. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Ravandi F; Roboz GJ; Wei AH; Döhner H; Pocock C; Selleslag D; Montesinos P; Sayar H; Musso M; Figuera-Alvarez A; Safah H; Tse W; Sohn SK; Hiwase D; Chevassut T; Pierdomenico F; La Torre I; Skikne B; Bailey R; Zhong J; Beach CL; Dombret H
J Hematol Oncol; 2021 Aug; 14(1):133. PubMed ID: 34454540
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Kobayashi Y; Munakata W; Ogura M; Uchida T; Taniwaki M; Kobayashi T; Shimada F; Yonemura M; Matsuoka F; Tajima T; Yakushijin K; Minami H
Int J Hematol; 2018 Jan; 107(1):83-91. PubMed ID: 28905323
[TBL] [Abstract][Full Text] [Related]
30. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
Chai S; Zhan JL; Zhao LM; Liu XD
Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
[TBL] [Abstract][Full Text] [Related]
31. Analysis of Adverse Drug Reaction Risk in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database.
Chisaki Y; Aoji S; Yano Y
Biol Pharm Bull; 2017; 40(6):824-829. PubMed ID: 28566626
[TBL] [Abstract][Full Text] [Related]
32. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019.
Ye X; Hu F; Zhai Y; Qin Y; Xu J; Guo X; Zhuang Y; He J
Hematol Oncol; 2020 Oct; 38(4):565-575. PubMed ID: 32383782
[TBL] [Abstract][Full Text] [Related]
33. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Online Patient Reviews and National Pharmacovigilance Data for Tramadol-Related Adverse Events: Comparative Observational Study.
Park S; Choi SH; Song YK; Kwon JW
JMIR Public Health Surveill; 2022 Jan; 8(1):e33311. PubMed ID: 34982723
[TBL] [Abstract][Full Text] [Related]
35. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database.
Caldito NG; Shirani A; Salter A; Stuve O
Mult Scler; 2021 Jun; 27(7):1066-1076. PubMed ID: 32820687
[TBL] [Abstract][Full Text] [Related]
36. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Liu Y; Dong C; He X; Shu Y; Wu P; Zou J
J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646
[TBL] [Abstract][Full Text] [Related]
37. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
38. Adverse event profiles of drugs used for treatment of juvenile idiopathic arthritis according to spontaneous reporting system database.
Niinomi I; Oyama S; Inada A; Wakabayashi T; Hirai T; Kambara H; Iida T; Uchida M; Sano Y; Hosohata K
Int J Clin Pharmacol Ther; 2022 Sep; 60(9):402-407. PubMed ID: 35924642
[TBL] [Abstract][Full Text] [Related]
39. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
40. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.
Shu Y; He X; Wu P; Liu Y; Ding Y; Zhang Q
Front Public Health; 2022; 10():996179. PubMed ID: 36339230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
